RhumbLine Advisers’s SQZ Biotechnologies Company SQZ Stock Holding History

RhumbLine Advisers’s Portfolio SQZ Stock Details SQZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-25,148	Closed	-$121K	–	3302
2022 Q1	$121K	Sell	25,148 -1,335	-5%	-$8.48K	﹤0.01%	2854
2021 Q4	$236K	Sell	26,483 -403	-1%	-$4.94K	﹤0.01%	2787
2021 Q3	$388K	Buy	26,886 +1,050	+4%	+$14.2K	﹤0.01%	2668
2021 Q2	$373K	Buy	+25,836	New	+$338K	﹤0.01%	2693

Other funds holding SQZ

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

AIG

American International Group New York $609M AUM 23.67% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

NanoDimension Woodside, California $24.7M AUM 74.01% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RhumbLine Advisers's SQZ Position: Q2 2022 in Review

RhumbLine Advisers sold out of SQZ Biotechnologies Company (SQZ) in Q2 2022, closing a stake of 25,148 shares — an estimated $121K sold.

RhumbLine Advisers first reported a position in SQZ in Q2 2021 and held it in 4 quarters. The position peaked at $388K in Q3 2021. 53 funds tracked by Wall St. Rank hold SQZ as of Q2 2022.

RhumbLine Advisers reported no remaining SQZ Biotechnologies Company position as of Q2 2022 after selling out during the quarter.
RhumbLine Advisers sold 25,148 SQZ Biotechnologies Company shares in Q2 2022, an estimated $121K.
RhumbLine Advisers first reported a position in SQZ Biotechnologies Company in Q2 2021 and held it in 4 quarters.
RhumbLine Advisers's SQZ Biotechnologies Company position peaked at $388K in Q3 2021.
53 funds tracked by Wall St. Rank held SQZ Biotechnologies Company as of Q2 2022.

Based on RhumbLine Advisers's 13F filing for Q2 2022, filed 11 Aug 2022.